ProMetic Life Sciences (TSE:PLI) Has Just Had Its Target Heightened by Investment Analysts at Paradigm Research to $5.50

Share

Stock Analysis:ProMetic Life Sciences (TSE:PLI) Price Target Change

In a recent research report issued to clients and investors by Paradigm Research on 3 December, ProMetic Life Sciences (TSE:PLI) had its PT boosted to $5.50. The firm currently has a solid Buy rating on shares.

From a total of 6 analysts covering ProMetic Life Sciences Inc. (TSE:PLI) stock, 6 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. The highest target price is $7.51 while the lowest target price is $3.2. The mean of all analyst targets is $4.2 with a 23.41% above today’s ($2.99) stock price. ProMetic Life Sciences Inc. was the topic of 6 analyst reports since August 10, 2015 according to the firm StockzIntelligence Inc. Paradigm Research reinitiated shares on September 28 with “Buy” rating.

Approximately 2.32M shares of stock traded hands or 4.50% up from the average. ProMetic Life Sciences Inc. (TSE:PLI) has risen 28.45% since April 30, 2015 and is uptrending. It has outperformed by 28.74% the S&P500.

ProMetic Life Sciences (TSE:PLI) Has Just Had Its Target Heightened by Investment Analysts at Paradigm Research to $5.50

ProMetic Life Sciences Inc. is a Canada biopharmaceutical company. The company has a market cap of $1.74 billion. The Firm offers solutions in bioseparations, plasma-derived therapeutics and small-molecule drug development. It currently has negative earnings. ProMetic offers its technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens.

COMMENTS: